Tempus AI, Inc. (NASDAQ:TEM) Major Shareholder Sells $6,052,024.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) major shareholder Bradley A. Keywell sold 170,720 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $35.45, for a total value of $6,052,024.00. Following the completion of the transaction, the insider now directly owns 15,993,729 shares in the company, valued at approximately $566,977,693.05. This represents a 1.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Tempus AI Stock Up 1.2 %

Shares of Tempus AI stock opened at $35.15 on Friday. The company’s 50-day moving average price is $46.03 and its 200-day moving average price is $47.10. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $79.49. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TEM. Kovitz Investment Group Partners LLC bought a new position in shares of Tempus AI in the third quarter worth approximately $1,367,000. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Tempus AI by 1,591.2% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock worth $68,922,000 after acquiring an additional 1,145,698 shares during the last quarter. Captrust Financial Advisors purchased a new position in Tempus AI in the third quarter worth $2,726,000. Sigma Planning Corp bought a new position in Tempus AI in the third quarter valued at $1,323,000. Finally, Dakota Wealth Management purchased a new stake in Tempus AI during the third quarter valued at about $1,185,000. 24.22% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Guggenheim started coverage on shares of Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price target on the stock. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and boosted their target price for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Piper Sandler restated a “neutral” rating and set a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Loop Capital dropped their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Wolfe Research began coverage on Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $56.36.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.